Skip to main content

Sema4: Joel Sendek

Sema4 has appointed Joel Sendek as chief financial officer.

Sendek brings more than 25 years of financial experience in the pharmaceutical and biotechnology sector, including overseeing successful initial public offerings at his last two companies.

Previously, Sendek was CFO at Spero Therapeutics and Forward Pharma. He spent more than 15 years as an equities research analyst at Stifel Financial and Lazard, worked in corporate development at Progenics Pharmaceuticals, and was an investment banking analyst at Goldman Sachs. He holds a BA in biochemistry from Rice University.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.